Company intelligence / Profile preview

NOEMS

Basel, Switzerland

Ownership: Private
Development stage: Commercial

Overview

Noema Pharma has four active Phase 2 clinical trials targeting severe pain in trigeminal neuralgia, seizures in tuberous sclerosis complex, Tourette syndrome, and vasomotor/CNS-mediated symptoms of menopause. Key data readouts are expected in 2025. Preclinical validation studies have been completed for atypical depression and binge eating disorders.

Therapeutic areas: PsychiatryRare DiseasesNeurologyWomen's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on NOEMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOEMS.

Explore the full profile